BioSpace News Archive

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”.

Tivic Health ® Systems, Inc. announced today that enrollment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed.

poLight ASA announced that PhenoSys, a leader in engineering and market innovative technology for animal behaviour research, offers a Mini2P turnkey solution that includes TLens® for optimal microscopic imaging.

Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.

RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council.

HSS Florida, part of world leader in orthopedics Hospital for Special Surgery, has appointed experienced executive and Registered Nurse Heather Woolf as Vice President and senior administrator for its teams and facilities in Palm Beach County.

Blacksmith Medicines, Inc. announced the release of $3.3M from its contract with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Department of Health and Human Services, to conduct IND-enabling and Phase 1 studies of FG-2101, its novel non-hydroxamate LpxC inhibitor, using both intravenous and oral administration for the treatment of urinary tract infections caused by multidrug-resistant Gram-negative bacteria.

Rgenta Therapeutics (“Rgenta” or the “Company”) today announced it will participate at the 19th Annual Huntington’s Disease Therapeutics Conference being held February 26-29, 2024, in Palm Springs, California.

Topline Results Expected in Q2 2024

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 2023 Top 50 Company.